Dual-targeting strategy using trastuzumab and lapatinib in a patient with HER2 gene amplification in recurrent metachronous metastatic gallbladder carcinoma.
Minfeng YeJieqing LvGuangen XuWei WangYuanming JingAijing SunZengxin LuXue WuYichuan LiuYang W ShaoFang LiuFeng TaoPublished in: The Journal of international medical research (2019)
Gallbladder carcinoma (GBC) is a rare and highly aggressive tumor. Early diagnosis is challenging, which results in a poor prognosis using systemic therapy. Recent studies have identified a subset of GBC patients with HER2 gene (ERBB2) amplification that could benefit from HER2-targeted therapy. Here, we report one patient with recurrent metachronous GBC with metastasis, who received the combination of trastuzumab and lapatinib. This approach achieved a partial response for both the brain and the lung metastases. This study demonstrated that HER2 inhibition is a promising therapeutic strategy for GBC with HER2 amplification and, combined with lapatinib, it can effectively target brain metastasis.
Keyphrases
- poor prognosis
- metastatic breast cancer
- nucleic acid
- positive breast cancer
- long non coding rna
- case report
- resting state
- copy number
- white matter
- genome wide
- squamous cell carcinoma
- small cell lung cancer
- functional connectivity
- label free
- stem cells
- tyrosine kinase
- cerebral ischemia
- cancer therapy
- gene expression
- blood brain barrier
- bone marrow